Dazdotuftide is under clinical development by Tarsier Pharma and currently in Phase III for Glaucoma. According to GlobalData, Phase III drugs for Glaucoma have a 43% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Dazdotuftide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Dazdotuftide overview

dazdotuftide (TRS-01) is under development for treatment of non-infectious anterior uveitis, uveitic glaucoma, post-cataract inflammation and autoimmune-related dry eye. It is administered by ophthalmic route as drops. The drug candidate is developed based on TRS Platform Technology. It is a new chemical entity (NCE). It acts by targeting NRP1, TLR, and ACE-2.

Tarsier Pharma overview

Tarsier Pharma (Tarsier), a subsidiary of Sun Pharmaceutical Industries Ltd, is a biopharmaceutical company dedicated to the development and commercialization of a breakthrough therapeutic approach for better and safer treatment of autoimmune and inflammatory ocular diseases.

For a complete picture of Dazdotuftide’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.